Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck, Schering Face Investigations by Congress and Plaintiffs Firm Over Vytorin Trial Results

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

A law firm considers filing suit to help consumers get money back from their Vytorin purchases, and two House members begin investigating the companies for withholding clinical findings.

You may also be interested in...



Merck Maintains Growth Trajectory For Vytorin, Zetia – For Now

Company gets subpoenas from New York State Attorney General, acknowledges as many as 50 civil class action suits over ENHANCE trial.

Merck Maintains Growth Trajectory For Vytorin, Zetia – For Now

Company gets subpoenas from New York State Attorney General, acknowledges as many as 50 civil class action suits over ENHANCE trial.

Merck/Schering Suspend TV Ads For Vytorin, Zetia; Congress Continues To Investigate ENHANCE

In wake of ENHANCE study, firms launch print consumer campaign to emphasize drugs’ benefit for LDL cholesterol, Schering-Plough tells “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS066741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By